MALVERN, Pa., Oct. 19 /PRNewswire/ -- Cutanea Life Sciences, an emerging specialty pharmaceutical company focused on improving human health and appearance through the development and commercialization of treatments for diseased and aging skin conditions, today announced that Robert Bitterman, the Company’s President and Chief Executive Officer, will be presenting at the Paramount BioSciences Healthcare Conference on Tuesday, October 23, at 10:45 a.m. EDT at the Waldorf=Astoria Hotel in New York City. Mr. Bitterman will provide a company overview and update on the status of Cutanea’s current development programs.
Those who are interested in attending may visit www.paramountbio.com/hcare2007 to register. Or, contact Ms. Tara Crosson of Paramount BioSciences at tcrosson@paramountbio.com or (212) 554-4351.
About Cutanea
Cutanea Life Sciences is an emerging specialty pharmaceutical company focused on improving human health and appearance through the development and commercialization of treatments for diseased and aging skin conditions. Its core strategy is to in-license novel, patented, mid-stage treatment candidates for aggressive development as potential market-leading dermatologic treatments for commercialization or out-license. The Company focuses on leveraging each of its products to address a variety of indications that serve the collective interest of patients and medical professionals.
Cutanea Life Sciences is a member of the family of bio/pharmaceutical companies founded by Paramount BioSciences, LLC.
sephraim@theruthgroup.comjrando@theruthgroup.com
CONTACT: Sara Ephraim (investors), +1-646-536-7002,
sephraim@theruthgroup.com, or Jason Rando (media), +1-646-536-7025,
jrando@theruthgroup.com, both of The Ruth Group, for Cutanea Life Sciences
Web site: http://www.paramountbio.com/hcare2007//
